Evidence map›Paper›PMID 28878218›Full record

ArticleScientific reports2017

Lack of Evidence for Vasoactive and Inflammatory Mediators in the Promotion of Macular Edema Associated with Epiretinal Membranes.

Brooks P Applewhite, Savalan Babapoor-Farrokhran, David Poon, Syed Junaid Hassan, Elizabeth Wellmann, Howard S Ying, Gregg L Semenza, Silvia Montaner, Akrit Sodhi

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact, top 80% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Brooks P ApplewhiteWilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA.
Savalan Babapoor-FarrokhranWilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA.
David PoonWilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA.
Syed Junaid HassanWilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA.
Elizabeth WellmannWilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA.
Howard S YingDepartment of Ophthalmology, Boston University School of Medicine, Boston, MA, 02346, USA.
Gregg L SemenzaDepartment of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States.
Silvia MontanerDepartment of Oncology and Diagnostic Sciences, School of Dentistry, University of Maryland, Baltimore, Maryland, United States.
Akrit SodhiWilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA. asodhi1@jhmi.edu.ORCID 0000-0001-5441-1014
Johns Hopkins University · USBoston University · USUniversity of Maryland, Baltimore · US

Funding

Promotion of retinal vascular hyperpermeability and macular edema by ANGPTL4R01EY025705 · NEI · UNIVERSITY OF MARYLAND BALTIMORE · PI MONTANER, SILVIA V · 2016 to 2020
$2.6M
HIF dysregulation as a novel genetic model to study retinal neovascular disease.K08EY021189 · NEI · JOHNS HOPKINS UNIVERSITY · PI SODHI, AKRIT SINGH · 2011 to 2015
$898k
NEI NIH HHS K08 EY021189NEI NIH HHS R01 EY025705
6 · The paper itself

Abstract

The development of symptoms in patients with epiretinal membranes (ERMs) often corresponds with the accumulation of interstitial fluid in the retina [i.e., the development of macular edema, (ME)]. To explore the potential value of pharmacologic therapeutic options to treat ME in patients with ERMs, we examine here the expression of vasoactive and inflammatory mediators in the vitreous of patients with idiopathic ERMs. We observed that vitreous concentrations of classic vasoactive factors (e.g., vascular endothelial growth factor) were similar in ERM patients with ME compared to controls. Using an array assessing the expression of 102 inflammatory cytokines we similarly did not observe a marked difference in cytokine expression in the vitreous of most ERM patients with ME compared to control patients. While the array data did implicate a group of inflammatory cytokines that were elevated in a subset of ERM patients who had severe ME (central subfield thickness ≥450 μm on spectral domain optical coherence tomography), expression of 3 of these inflammatory cytokines, all previously implicated in the promotion of ME in ischemic retinal disease, were not elevated by quantitative enzyme-linked immunosorbent assay. We conclude that therapies modulating vasoactive mediators or inflammatory cytokines may not affect ME in ERM patients.

Indexed as

BiomarkersAngiopoietinsCapillary PermeabilityCytokinesEpiretinal MembraneFluorescein AngiographyGene ExpressionHumansInflammation MediatorsMacular EdemaRetinal VesselsTomography, Optical CoherenceVascular Endothelial Growth Factor AAngiopoietinsBiomarkersCytokinesInflammation MediatorsVascular Endothelial Growth Factor A

Identifiers

PMID28878218
PMCPMC5587698
OpenAlexW2753872146

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.